Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

The Tendyne system is designated for those who are at high risk for traditional open-heart surgery. It helps with those with ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

US FDA approves Abbott’s Tendyne, first-of-its-kind device to replace the mitral valve without open-heart surgery: Abbott Park, Illinois Thursday, May 29, 2025, 16:00 Hrs [IST] ...

Abbott said the Tendyne system addresses a significant unmet need in cardiac care, providing an option for patients ineligible for open heart surgery and whose valves cannot be successfully repaired ...

The results of mitral valve repair for structural disease are durable and are generally accepted to be superior to mitral valve replacement. Following the early pioneering work of Carpentier ...

A fibrous ring secures it to the walls of the left ... and in three months it will be as strong as it ever was. A mitral valve repair costs the NHS £10,000, including hospital stay, six-week ...

There were no primary safety events in the ViR (Valve in Ring) group ... Track Obstruction During Transeptal Transcatheter Mitral Valve Replacement" ...

May 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR ...